Champions Oncology Inc Q1 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst : Good afternoon and thank you for taking the questions and congratulations on the strong quarter. Maybe first up, I'd love it if you could provide a little bit of color on what you're hearing from customers. I think you noted that the funding environment has gotten a little bit better. But what are you hearing from customers? And even if you could delineate that between the smaller, midsize customers versus larger customers, there's been some -- I don't want to say concern, but some comments here recently regarding the larger customers' reprioritization of pipelines, those types of things. I'm just curious what you're hearing?

Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst : Okay. That's much appreciated. Last quarter, you noted that the conversion rates were improving. Cancellation rates were down. Did that trend continue here into the first quarter? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 11, 2024 / 8:30PM, CSBR.OQ - Q1 2025 Champions Oncology Inc Earnings Call

Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst : That's great. And maybe one last one, and I'll hop back in the queue. But on Monday afternoon, the BIOSECURE Act was passed in the House, now it moves on to the Senate. I'm just curious, do you guys compete against one or more of the entities listed in that bill? And if so, would their being blocked in the ¡ here in the US market, would that create an opportunity for you to pick up some share? Thank you.

Question: Matt Hewitt - Craig-Hallum Capital Group LLC - Analyst : Got it. Well, that's great news. Thank you.